wheel
1.6 years
67% of patients with GA lose the ability to drive*5
bcva_icon
2 years
50% of patients with GA lose 2 lines of vision6
Geographic Atrophy (GA) Central fovea
2.5 years
for GA to reach
the central fovea7

GA may impact patients sooner than you expect

Every year, patients with GA can experience further disease progression and loss of photoreceptors, resulting in changes to visual function that can affect daily activities and may ultimately lead to loss of independence.4-6,8
patients_undiagnosed
1.5 million patients in the US live with GA, but 75% of patients are undiagnosed.9,10

Early detection means early protection

A comprehensive eye examination with imaging can help with early detection, diagnosis, and monitoring of GA. GA is a heterogeneous disease, so it’s important to be vigilant and look for key biomarkers in the imaging modalities you have in your office.
Colour Fundus Photography
Color Fundus Photography (CFP)
  1. Sharply demarcated, typically circular zone with increased choroidal vessel visibility
Fundus Autofluorescence
Fundus Autofluorescence (FAF)
  1. Hypofluorescence with a sharply demarcated border
  2. Hyperfluorescence surrounding atrophic lesion can indicate lipofuscin accumulation and prognostic of GA progression
Optical Coherence Tomography
Optical Coherence Tomography (OCT)
  1. Choroidal hypertransmission
  2. RPE, photoreceptor, and choriocapillaris layer loss
Download our Imaging Guide
*Bilateral GA.
RPE=retinal pigment epithelium.
Images courtesy of Dr Mark Dunbar.

Sign up for updates

Sign Up

Explore our efficacy data

Next Page
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.